Echosens Announces FibroScan Optimized Market Access Initiative
By Business Wire
WALTHAM, Mass.--(BUSINESS WIRE)--#FibroScan--Echosens, a high-technology company offering the FibroScan® portfolio of solutions, expands its commitment and support for customers with the launch of the FibroScan Optimized Market Access Initiative, including a dedicated team to optimize and efficiently integrate utilization of FibroScan in their practice settings. This holistic initiative provides robust tools for improving access to care by ensuring patients can receive early, noninvasive assessment and monitoring of liver disease with FibroScan, the preferred non-invasive test referenced by over 3,500 peer-reviewed publications and 160 international guidelines including American Gastroenterological Association (AGA), American Association of Clinical Endocrinology (AACE) and American Heart Association (AHA).
“We are redefining market access and expanding the value of FibroScan to serve and improve access to care for new and existing patients as part of the diagnostic pathway for non-alcoholic liver disease (NAFLD) and the more advanced nonalcoholic steatohepatitis (NASH),” says Jon Gingrich, CEO, Echosens North America. “The new FibroScan Market Access Initiative exemplifies our Company’s deep and thoughtful commitment to advancing better patient care, improving access to clinical services and sustaining opportunities to halt the progression of liver disease.”
The FibroScan Optimized Market Access Initiative is centered around enhanced partnerships and better access to quality care by now offering a dedicated team of professionals as well as impactful materials, inclusive of an updated coding and billing guide, to assist clinicians in implementing FibroScan into their practice. For more information, visit https://www.echosens.com/en-us/market-access/.
“With our profound commitment to innovation and a patient-centered approach that advances access to comprehensive, high-quality healthcare services, we look forward to further supporting an improved patient experience and enhanced health outcomes,” says Gingrich. “The FibroScan Optimized Market Access Initiative reflects our alignment and shared goals with clinician partners to provide better care for patients and exceptional liver health management.”
Echosens, the developer of FibroScan®, is an innovative high-technology company offering a full range of products and services supporting physicians in their assessment and management of patients with chronic liver diseases. FibroScan is supported by over 3,500 peer-reviewed publications and examinations are covered by Medicare, Medicaid and many insurance plans. For more information, please visit https://www.echosens.com/.
201.641.1911 x 14
Liked what you read? Head to the TechDogs homepage to find the latest tech content infused with drama and entertainment. We've got Articles, White Papers, Case Studies, Reports, Videos and Events that help you Know Your World of Technology.
First published on Mon, Sep 19, 2022
Disclaimer - Reference to any specific product, software or entity does not constitute an endorsement or recommendation by TechDogs nor should any data or content published be relied upon. The views expressed by TechDogs’ members and guests are their own and their appearance on our site does not imply an endorsement of them or any entity they represent. Views and opinions expressed by TechDogs’ Authors are those of the Authors and do not necessarily reflect the view of TechDogs or any of its officials. All information / content found on TechDogs’ site may not necessarily be reviewed by individuals with the expertise to validate its completeness, accuracy and reliability.
Join The Discussion